News

February 21, 2020February 21, 2020

Solanezumab and Gantenerumab Fail to Slow Memory Loss or Cognitive Decline in Early-onset Alzheimer’s, Study Finds

News

Two investigational treatments, solanezumab and gantenerumab, failed to prevent memory loss or cognitive decline in patients with a rare, inherited form of early-onset Alzheimer’s disease, who were enrolled in ... Read more

February 19, 2020February 19, 2020

Biogen to Start Re-dosing Aducanumab in Alzheimer’s Patients From Halted Trials

News

Biogen will soon launch an open-label trial to start re-dosing aducanumab — an injectable treatment under development — to patients with Alzheimer’s disease who participated in four studies halted ... Read more

February 18, 2020February 18, 2020

Number of Dementia Cases Likely to Double by 2050 as Europe Ages, Report Says

News

The number of people with dementia in 37 countries in and near Europe is likely to double to 18.8 million by 2050, according to Alzheimer Europe. That’s more than ... Read more

February 17, 2020February 17, 2020

Cortexyme Advances COR388 Clinical Development Program in Alzheimer’s Disease After FDA Meeting

News

Following feedback from the U.S. Food and Drug Administration (FDA), Cortexyme will conduct an interim analysis for effectiveness of its lead investigational therapy COR388, currently in the Phase 2/3 ... Read more

February 14, 2020February 14, 2020

Scientists Use CRISPR-Cas9 as ‘DNA Scissors’ to Cut Out Alzheimer’s Gene in Mice, Study Shows

News

Using the gene editing technology CRISPR-Cas9 like a pair of “DNA scissors,” researchers were able to essentially cut out the beta-secretase 1 (BACE1) gene in a mouse model of ... Read more

February 12, 2020February 12, 2020

Chaperone Works to Lessen Alzheimer’s Symptoms and Toxic Protein Buildup, Mouse Study Says

News

A molecular chaperone called TPT-172 was able to prevent proteins linked to Alzheimer’s — including amyloid-beta and tau — from building up in the brain, improve memory and ease brain inflammation when tested ... Read more

February 11, 2020February 11, 2020

Memory Health Awarded UK Patent as Alzheimer’s Treatment

News

The United Kingdom has awarded Memory Health a patent for a proprietary brain health supplement developed to prevent and treat neurodegenerative disease. Also called Memory Health, the all-natural nutritional ... Read more

February 10, 2020February 10, 2020

NIH Awards $4.8M Grant to Project Investigating the Role of ApoE4 Gene Variant in Alzheimer’s

News

The National Institutes of Health (NIH) has awarded a $4.8-million grant to support a project designed to discover how the ApoE4 gene variant, a known genetic risk factor for ... Read more

February 7, 2020February 7, 2020

Alzheimer’s Patients, Clinicians, Industry Representatives Urge Better Access to PET Scans

News

Physicians, industry representatives, and Alzheimer’s disease patients urged lawmakers in Washington to pass legislation they say will improve access to amyloid positron imaging tomography (PET) scans for the diagnosis, ... Read more

February 5, 2020February 5, 2020

Phase 1b Trial Begins to Test Alector’s Immune-system Targeting Antibody AL003 in Alzheimer’s Patients

News

A Phase 1b trial has started dosing Alzheimer’s patients with Alector’s candidate immune system-targeting therapy, called AL003, to evaluate its safety and tolerability, the company has announced. AL003 is ... Read more

Pin It on Pinterest